Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Debt (2017)

Aclaris Therapeutics has reported Total Debt over the past 1 years, most recently at $590000.0 for Q4 2017.

  • Quarterly results put Total Debt at $590000.0 for Q4 2017, changed N/A from a year ago — trailing twelve months through Dec 2017 was $590000.0 (changed N/A YoY), and the annual figure for FY2017 was $590000.0, changed.
  • Total Debt for Q4 2017 was $590000.0 at Aclaris Therapeutics.
  • Over the last five years, Total Debt for ACRS hit a ceiling of $590000.0 in Q4 2017 and a floor of $590000.0 in Q4 2017.